Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline?

Area of Science:

• Neurology
• Clinical Practice
• Healthcare Policy

Background:

• Recent advancements in diagnostics and disease-modifying therapies (DMTs) for multiple sclerosis (MS) present opportunities for improved patient outcomes.
• Variations in clinical practices and healthcare policies across European countries may impede timely and appropriate treatment initiation and modification for MS patients.

Purpose of the Study:

• To review and compare current multiple sclerosis (MS) clinical practices across European Union countries.
• To identify differences in treatment initiation for clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS) and in the timing of treatment switching or escalation.

Main Methods:

• Comparative review of current MS clinical practices in selected European Union countries.
• Analysis of national policies and clinical guidelines related to MS treatment initiation and modification.

Main Results:

• Significant variations exist among European countries regarding the initiation of disease-modifying therapies (DMTs) in early MS (CIS/RRMS).
• Differences were also observed in the timing and criteria for switching or escalating MS treatments.
• National policies and healthcare system structures appear to influence these variations in clinical practice.

Conclusions:

• A European-level treatment guideline for multiple sclerosis (MS) is needed to harmonize clinical practices.
• Such a guideline could inform national policies and facilitate the international dissemination of best practices in MS management.
• Developing a unified guideline would ultimately serve patients' interests by promoting more consistent and optimal care across Europe.